The efficiency of non-specific inhaled immunotherapy with ruzam in patients with atopic bronchialasthma

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. To study the efficacy and safety of inhaled form of ruzam in adult patients with persistent mild
and moderate atopic bronchial asthma (ba).
Materials and methods. a placebo-controlled prospective, randomized, open label study of an efficacy of ruzam
a solution for inhalations (in bottles on 2,5 or 5 ml) on 2,5 ml onсe a day through nebulizer during 2 weeks was
conducted in adult asthmatic patients. The efficacy of therapy was evaluated by dynamics of symptoms and requirement
in ƒ2-agonists, besides PEfr, spirometry, bronchial hyperresponsiveness (bhr), asthma control test
(aCT ), level of the markers of the allergic inflammation were performed.
Results. reduction of bа symptoms, increase morning PEfr, decrease of bhr and NОex level in patients who
received ruzam compared with control group was observed. achievement of clinical control of bа in patients
treated by ruzam was accompanied by statistically significant positive dynamics of markers of inflammation
(ifNg, ECP) in blood serum and in supernatant of the induced sputum. it testifies about anti-inflammatory influence
of ruzam.
Conclusion. inhaled therapy with ruzam in a complex with iNCs basic therapy is an effective and safe method
of treatment of persistent atopic bronchial asthma. This combination allows to reach clinical and functional
control of ba faster and to reduce inflammation markers in blood serum and induced sputum.

About the authors

D V Terekhov

Nataliya Mikhaylovna Nenasheva

Email: 144403@gmail.com

D V Terekhov

Russian Medical Academy of Postgraduate Education

Russian Medical Academy of Postgraduate Education

N M Nenasheva

Russian Medical Academy of Postgraduate Education

Russian Medical Academy of Postgraduate Education

References

  1. Глобальная Стратегия лечения и профилактики бронхиальной астмы (GINA) пересмотр 2006 г. Пер. с англ. М., «Атмосфера». 2007.
  2. Pellegrino R. et al. Lung function test interpretation. Eur. Respir. J. 2005, v. 26, p. 948-968.
  3. Aйсанов З.Р., Калманова Е.H. Легочные функциональные тесты в диагностике бронхиальной астмы. Клинические рекомендации. Бронхиальная астма. М., «Атмосфера». 2008, с. 78-96.
  4. Чучалин А.Г. Стандартизация тестов исследования легочной функции. Пульмонология. Приложение. 1993, с. 61-62.
  5. American Thoracic Society Documents ATS/ERS: Recommendation for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory NitricOxide and Nasal Nitric Oxide, 2005. Am. J. Respir. Crit. Care.Med. 2005, v. 171, р. 912-930.
  6. Белевский А.С., Княжеская Н.П., Новиков Ю.К. Оценка контроля бронхиальной астмы с помощью АСТ-теста. «Атмосфера». Пульмонология и аллергология. 2007, № 1, с. 43-47.
  7. Реброва О.Ю. Статистический анализ медицинских данных. М., «Медиа Сфера». 2006, c. 312.
  8. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт». 1998, 252 с.
  9. Holgate S.T. et al. Asthma: Physiology, Immunology and Treatment. London: Academic Press. 2003, p. 3-25.
  10. Осипова Г.Л. Рузам в комплексной терапии аллергических заболеваний. Пульмонология и аллергология. 2002, № 2, с. 32-33.

Statistics

Views

Abstract: 131

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright © Pharmarus Print Media, 2011



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies